ROYALTY PHARMA PLC

Royalty Pharma CFO’s Massive 10‑b‑5‑1 Sale Raises Eyebrows Ahead of Q4 Earnings Flash

Explore how Royalty Pharma’s CFO Coyne’s latest 10‑b‑5‑1 insider sale may signal future earnings momentum or market caution, and what it means for investors.

ROYALTY PHARMA PLC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

04/02/2026, 23:23

4 minutes to read

Royalty Pharma’s EVP Unwinds 20,000 Shares Amid Teva Deal, Raising Shareholder Concerns over Insider Selling Trend

Royalty Pharma insiders sell shares at flat prices amid new Teva deal – understand the structured sales, valuation, and long‑term royalty upside for investors.

ROYALTY PHARMA PLC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

13/01/2026, 23:53

3 minutes to read

Newer articles